Rare diseases
Investigational molecules
Locations
Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors
AustriaA Phase II Study of Cadonilimab Plus Lenvatinib Versus Lenvatinib in Advanced Hepatocellular Carcinoma After Atezolizumab/Bevacizumab Progression
FranceA study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.
BelgiumA study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed
FranceStudy of pembrolizumab and lenvatinib treatment for patients with vulvar cancer
ItalyStudy of Pembrolizumab and Lenvatinib for Patients with Advanced Vulvar Cancer Not Suitable for Surgery or Radiotherapy
GermanyStudy on the Effects of Tumor Removal in Patients with Metastatic Kidney Cancer Treated with Nivolumab and Ipilimumab Combination
ItalyStudy of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma
AustriaStudy of Lenvatinib for Patients with Poor-Prognosis Hepatocellular Carcinoma Undergoing Percutaneous Ablation Therapy
FranceStudy on the Safety and Effects of Farletuzumab Ecteribulin for Patients with Ovarian, Breast, Endometrial, and Lung Cancer
FranceStudy of E7386 and Lenvatinib for Patients with Liver, Colon, Endometrial, or Other Solid Tumors
DenmarkStudy on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma
The NetherlandsTell us about your condition – we search every trial in Europe and connect you with the right site.
